Dasatinib

Chemical formula: C₂₂H₂₆ClN₇O₂S  Molecular mass: 488.006 g/mol  PubChem compound: 3062316

Therapeutic indications

Dasatinib is indicated for:

Chronic myelogenous leukaemia (CML) Philadelphia chromosome positive (Ph+)

Population group: only adults (18 years old or older)

Dasatinib is indicated for the treatment of adult patients with:

  • newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.
  • chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib.
  • Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.

Dasatinib is indicated for the treatment of paediatric patients with:

  • newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.
  • newly diagnosed Ph+ ALL in combination with chemotherapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Chronic myelogenous leukaemia (CML) Philadelphia chromosome positive (Ph+)

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Dasatinib is indicated for the treatment of adult patients with:

  • newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.
  • chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib.
  • Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.

Dasatinib is indicated for the treatment of paediatric patients with:

  • newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.
  • newly diagnosed Ph+ ALL in combination with chemotherapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2020: SPRYCEL Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈